Dual Therapy of Ovarian Cancer Using Measles Viruses Expressing Carcinoembryonic Antigen and Sodium Iodide Symporter
Open Access
- 15 March 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (6) , 1868-1875
- https://doi.org/10.1158/1078-0432.ccr-05-1803
Abstract
Purpose: MV-CEA is an oncolytic measles virus currently being tested in patients with ovarian cancer and whose propagation can be monitored by measuring blood carcinoembryonic antigen (CEA) levels. MV-NIS is an oncolytic measles virus coding for the thyroidal sodium iodide symporter (NIS) whose propagation can be mapped by serial radioiodine imaging. Expression of both CEA and NIS genes from a single virus would combine sensitive, quantitative expression monitoring (CEA) with radioisotopic expression mapping (NIS). Because of the unfavorable replication kinetics of measles viruses expressing both CEA and NIS, we explored the feasibility of combining MV-CEA with MV-NIS for comprehensive virotherapy monitoring in ovarian cancer.Keywords
This publication has 27 references indexed in Scilit:
- Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancerCancer Gene Therapy, 2005
- In vivo Radioiodide Imaging and Treatment of Breast Cancer Xenografts after MUC1-Driven Expression of the Sodium Iodide SymporterClinical Cancer Research, 2005
- Oncolysis of human ovarian cancers by echovirus type 1International Journal of Cancer, 2005
- Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapyThe Journal of Gene Medicine, 2004
- Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirusGene Therapy, 2004
- Genetically targeted radiotherapy of head and neck squamous cell carcinoma using the sodium-iodide symporter (NIS)Head & Neck, 2004
- Molecular Imaging: Looking at Problems, Seeing SolutionsScience, 2003
- Gene Therapy for Killing p53-Negative Cancer Cells: Use of Replicating Versus Nonreplicating AgentsHuman Gene Therapy, 2003
- Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene-Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian CancerJournal of Clinical Oncology, 2002
- Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 statusGene Therapy, 2000